Form 6K Sanofi ADR For: 15 April
- Investing.com
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Sanofi SA (SASY)
This is the main Sanofi stock price chart and current quotes. You can find more details about SASY stock by going to one of our multiple sections under this page such as historical data, price charts, technical analysis and others.
81.11
+0.09(+0.11%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
81.02
82.39
52 wk Range
74.85
98.36
Earnings results expected in 7 days
1/3
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
81.0282.39
52 wk Range
74.8598.36
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(5.09%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(5.09%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SASY Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
96.18
Upside
+18.58%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High shareholder yield
- Sanofi-aventis receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Form 6K Sanofi ADR For: 15 April
- Investing.com
- Sanofi-aventis receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine’s AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV’574, for treatment of ulcerative colitis and Crohn’s disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Compare SASY to Peers and Sector
Metrics to compare | SASY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSASYPeersSector | |
|---|---|---|---|---|
P/E Ratio | 20.1x | 19.7x | −0.5x | |
PEG Ratio | 0.45 | 0.96 | 0.00 | |
Price / Book | 1.4x | 1.5x | 2.6x | |
Price / LTM Sales | 2.1x | 2.4x | 3.2x | |
Upside (Analyst Target) | 23.4% | 14.8% | 45.7% | |
Fair Value Upside | Unlock | 21.2% | 4.8% | Unlock |
Analyst Ratings
14 Buy
10 Hold
0 Sell
Ratings:
24 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 96.18
(+18.58% Upside)
Earnings
Latest Release
Jan 29, 2026
EPS / Forecast
1.53 / 1.44
Revenue / Forecast
11.75B / 11.63B
People Also Watch
FAQ
What Is the Sanofi (SASY) Stock Price Today?
The Sanofi stock price today is 81.11 EUR.
What Stock Exchange Does Sanofi Trade On?
Sanofi is listed and trades on the Paris Stock Exchange.
What Is the Stock Symbol for Sanofi?
The stock symbol for Sanofi is "SASY."
Does Sanofi Pay Dividends? What’s The Current Dividend Yield?
The Sanofi dividend yield is 5.09%.
What Is the Sanofi Market Cap?
As of today, Sanofi market cap is 97.94B EUR.
What Is Sanofi's Earnings Per Share (TTM)?
The Sanofi EPS (TTM) is 4.03.
When Is the Next Sanofi Earnings Date?
Sanofi will release its next earnings report on Apr 23, 2026.
From a Technical Analysis Perspective, Is SASY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Sanofi Stock Split?
Sanofi has split 0 times.
How Many Employees Does Sanofi Have?
Sanofi has 74846 employees.
What is the current trading status of Sanofi (SASY)?
As of Apr 16, 2026, Sanofi (SASY) is trading at a price of 81.11 EUR, with a previous close of 81.11 EUR. The stock has fluctuated within a day range of 81.02 EUR to 82.39 EUR, while its 52-week range spans from 74.85 EUR to 98.36 EUR.
What Is Sanofi (SASY) Price Target According to Analysts?
The average 12-month price target for Sanofi is 96.18 EUR, with a high estimate of 112 EUR and a low estimate of 57 EUR. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +18.58% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.